CompletedPhase 2

Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Canada1 participantsStarted 2021-03-11

Plain-language summary

This is a single participant study of decidual stromal cells (DSC) for the treatment of steroid refractory graft-versus-host disease (GVHD) in a patient with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

A single participant with myelodysplastic syndrome/myeloproliferative neoplasm located at Princess Margaret Cancer Centre who experienced steroid-refractory graft-vs-host disease after receiving an allogeneic hematopoietic cell transplant and have no standard treatment options available.

What they're measuring

Eastern Cooperative Oncology Group Performance Status Score

Timeframe: 6 weeks

Karnofsky Performance Score

Timeframe: 6 weeks

Graft-Versus-Host Disease Severity

Timeframe: 6 weeks

Aspartate Transaminase levels

Timeframe: 6 weeks

Alanine aminotransferase levels

Timeframe: 6 weeks

Alkaline phosphatase levels

Timeframe: 6 weeks

Bilirubin levels

Timeframe: 6 weeks

C-reactive protein levels

Timeframe: 6 weeks

Trial details

NCT IDNCT04926194

SponsorUniversity Health Network, Toronto

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-06-09

View on ClinicalTrials.gov More Myelodysplastic/Myeloproliferative Neoplasm trials